Abstract

Since the prioritization of Lymphatic Filariasis (LF) elimination in 1997, progress has been made in reducing disease transmission and burden. Validation of elimination through Transmission Assessment Surveys (TAS) in implementation units (IUs) that have received at least 5 rounds of mass drug administration (MDA) and achieved minimum threshold of 65% treatment coverage is required. There are IUs that do not qualify for TAS due to achievement of low treatment coverage. This study sought to identify barriers of community participation and access to MDA, develop and test strategies to be recommended for improved uptake. Two wards in Kaloleni sub-county, Kilifi county with an average treatment coverage of 56% in 2015, 50.5% in 2016 were purposively sampled and a quasi-experimental study conducted. Through systematic random sampling, 350 (pre-intervention) and 338 (post-intervention) household heads were selected and interviewed for quantitative data. For qualitative data, 16 Focus Group Discussions (FGDs) with purposively selected community groups were conducted. Participatory meetings were held with county stakeholders to agree on strategies for improved community participation in MDA. The quantitative data were analyzed using STATA version 14.1, statistical significance assessed by chi square test and qualitative data by QSR NVIVO version 10. The identified strategies were tested in experimental sites during the 2018 MDA and the usual MDA strategies applied in control sites. The results showed an increase in community participation and access to MDA in both sites 80.6% (pre-intervention), 82.9% (post-intervention). The proportion of participants who considered the treatment as necessary significantly (p = 0.001) increased to 96.2% from 88.3% and significantly dropped for those with drug swallowing problems associated with: size (p<0.001), number (p<0.027) and taste (p = 0.001). The implemented strategies may have contributed to increased participation and access to MDA and should be applied for improved treatment uptake. Health education on disease aetiology and importance of drug uptake in all rounds is key to program’s success.

Highlights

  • The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched over 15 years ago with the goal to interrupt transmission of the disease in endemic countries [1]

  • There are implementation units (IUs) in the LF endemic countries that have completed at least 5 effective mass drug administration (MDA) rounds to qualify for Transmission Assessment Surveys (TAS) in order to evaluate the level of LF transmission in the population and determine if MDA can be stopped [9]

  • Ethical clearance was received from the Kenya Medical Research Institute (KEMRI), Scientific and Ethics Review Unit (SERU) Protocol Number 3666 and written informed consent sought from all study participants

Read more

Summary

Introduction

The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched over 15 years ago with the goal to interrupt transmission of the disease in endemic countries [1]. The GPELF has the aim of interrupting LF transmission, managing morbidity and preventing disability and recommends annual community-wide MDA of antifilarial tablets; diethylcarbamazine citrate (DEC) or ivermecticin and albendazole to entire at-risk populations aged 2 years and above for 4 to 6 years at adequate levels of coverage, at least 65% of total population in endemic areas [2, 3]. There are IUs in the LF endemic countries that have completed at least 5 effective MDA rounds to qualify for TAS in order to evaluate the level of LF transmission in the population and determine if MDA can be stopped [9]. Perception of no need for LF drugs and dislike of taking too many tablets [10,11,12] are some reasons for low MDA coverage

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call